Taysha Gene Therapies (TSHA) News Today $2.46 -0.11 (-4.28%) Closing price 04:00 PM EasternExtended Trading$2.48 +0.02 (+0.77%) As of 06:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TSHA Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 Time Period Taysha Gene Therapies (NASDAQ:TSHA) Trading Down 4.9% - Here's WhyTaysha Gene Therapies (NASDAQ:TSHA) Shares Down 4.9% - Here's What HappenedJune 20 at 12:55 PM | marketbeat.comTaysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives Average Rating of "Buy" from BrokeragesShares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Get Free Report) have been given an average rating of "Buy" by the eight brokerages that are currently covering the firm, MarketBeat Ratings reports. Eight research analysts have rated the stock with a buy rating. The average 1 year price targetJune 19 at 4:43 AM | marketbeat.comEquities Analysts Offer Predictions for TSHA FY2025 EarningsTaysha Gene Therapies, Inc. (NASDAQ:TSHA - Free Report) - Research analysts at Cantor Fitzgerald raised their FY2025 EPS estimates for shares of Taysha Gene Therapies in a research report issued to clients and investors on Thursday, June 12th. Cantor Fitzgerald analyst K. Kluska now expects thatJune 16, 2025 | marketbeat.comMillennium Management LLC Makes New Investment in Taysha Gene Therapies, Inc. (NASDAQ:TSHA)Millennium Management LLC bought a new position in Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 151,614 shares of the company's stock, valued at approximately $262,000. MillennJune 12, 2025 | marketbeat.comTaysha Gene Therapies (NASDAQ:TSHA) Earns Buy Rating from Needham & Company LLCJune 12, 2025 | americanbankingnews.comTaysha Gene Therapies (NASDAQ:TSHA) Trading Up 10.5% - Time to Buy?Taysha Gene Therapies (NASDAQ:TSHA) Stock Price Up 10.5% - Time to Buy?June 11, 2025 | marketbeat.comCantor Fitzgerald Estimates TSHA FY2026 EarningsTaysha Gene Therapies, Inc. (NASDAQ:TSHA - Free Report) - Stock analysts at Cantor Fitzgerald issued their FY2026 earnings estimates for Taysha Gene Therapies in a report issued on Monday, June 9th. Cantor Fitzgerald analyst K. Kluska anticipates that the company will earn ($0.42) per share for tJune 11, 2025 | marketbeat.comTaysha Gene Therapies (NASDAQ:TSHA) Stock Price Down 5.9% - What's Next?Taysha Gene Therapies (NASDAQ:TSHA) Shares Down 5.9% - Should You Sell?June 10, 2025 | marketbeat.comNeedham & Company LLC Reaffirms "Buy" Rating for Taysha Gene Therapies (NASDAQ:TSHA)Needham & Company LLC reaffirmed a "buy" rating and issued a $8.00 price objective on shares of Taysha Gene Therapies in a research note on Tuesday.June 10, 2025 | marketbeat.comTaysha Gene Therapies Grants Stock Options to New Employees Under Inducement PlanJune 8, 2025 | nasdaq.comWellington Management Group LLP Purchases 122,402 Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA)Wellington Management Group LLP boosted its position in shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Free Report) by 26.4% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 585,594 shares of the company's stock afterJune 7, 2025 | marketbeat.comTaysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)June 6, 2025 | globenewswire.comSquarepoint Ops LLC Has $366,000 Position in Taysha Gene Therapies, Inc. (NASDAQ:TSHA)Squarepoint Ops LLC raised its stake in shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Free Report) by 105.4% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 211,842 shares of the company's stock after buying an addiJune 6, 2025 | marketbeat.comTaysha Gene Therapies, Inc. (NASDAQ:TSHA) Major Shareholder Buys $2,062,500.00 in StockTaysha Gene Therapies, Inc. (NASDAQ:TSHA - Get Free Report) major shareholder Paul B. Manning acquired 750,000 shares of the business's stock in a transaction on Friday, May 30th. The shares were bought at an average cost of $2.75 per share, with a total value of $2,062,500.00. Following the completion of the acquisition, the insider now owns 2,841,704 shares of the company's stock, valued at approximately $7,814,686. This trade represents a 35.86% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Major shareholders that own more than 10% of a company's shares are required to disclose their transactions with the SEC.June 5, 2025 | marketbeat.comTaysha Gene Therapies Releases TSHA-102 Clinical Program UpdatesJune 4, 2025 | insidermonkey.comTaysha Gene Therapies (NASDAQ:TSHA) Shares Gap Up on Insider Buying ActivityTaysha Gene Therapies (NASDAQ:TSHA) Shares Gap Up After Insider Buying ActivityJune 4, 2025 | marketbeat.comRetail Buzz Surges Around Taysha Gene Therapies After Positive Rett Syndrome Trial DataJune 4, 2025 | msn.comPaul B. Manning Buys 750,000 Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA) StockJune 4, 2025 | insidertrades.comTaysha Gene Therapies Highlights TSHA-102 Program Advancements for Rett Syndrome at 2025 IRSF Scientific MeetingJune 3, 2025 | quiverquant.comTaysha Gene Therapies Announces Details for Oral Presentations at the 2025 IRSF Rett Syndrome Scientific Meeting Reviewing Recent Updates from the TSHA-102 Clinical ProgramJune 3, 2025 | globenewswire.comTaysha Gene Therapies (NASDAQ:TSHA) Given "Buy" Rating at Needham & Company LLCNeedham & Company LLC reaffirmed a "buy" rating and set a $8.00 target price (up from $6.00) on shares of Taysha Gene Therapies in a report on Monday.June 3, 2025 | marketbeat.comTaysha Gene Therapies (NASDAQ:TSHA) Price Target Raised to $11.00Canaccord Genuity Group increased their price objective on Taysha Gene Therapies from $9.00 to $11.00 and gave the company a "buy" rating in a report on Tuesday.June 3, 2025 | marketbeat.com6TSHA : Where Taysha Gene Therapies Stands With AnalystsJune 3, 2025 | benzinga.comTaysha Gene Therapies, Inc. (NASDAQ:TSHA) Stake Lessened by Deutsche Bank AGDeutsche Bank AG cut its stake in Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Free Report) by 94.1% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 151,083 shares of the company's stock after sellinJune 2, 2025 | marketbeat.comBank of America Corp DE Boosts Position in Taysha Gene Therapies, Inc. (NASDAQ:TSHA)Bank of America Corp DE boosted its holdings in Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Free Report) by 1,178.9% during the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 1,710,303 shares of the company's stock after buying an additional 1,576,568 shares duringJune 1, 2025 | marketbeat.comTaysha Gene Therapies Announces Pivotal Part B Trial Design Details for TSHA-102 in Rett Syndrome Enabled by IRSF Natural History Data and Positive Clinical Data from Part A of ...May 30, 2025 | morningstar.comTaysha Gene Therapies (TSHA) Price Target Raised by JMP on Positive Rett Syndrome Trial DataMay 30, 2025 | msn.comTaysha Gene Therapies (NASDAQ:TSHA) Shares Gap Up on Analyst UpgradeTaysha Gene Therapies (NASDAQ:TSHA) Shares Gap Up Following Analyst UpgradeMay 30, 2025 | marketbeat.comJMP Securities Issues Positive Forecast for Taysha Gene Therapies (NASDAQ:TSHA) Stock PriceJMP Securities raised their target price on shares of Taysha Gene Therapies from $5.00 to $6.00 and gave the company a "market outperform" rating in a report on Thursday.May 30, 2025 | marketbeat.comChardan Capital Issues Positive Forecast for Taysha Gene Therapies (NASDAQ:TSHA) Stock PriceChardan Capital increased their price objective on Taysha Gene Therapies from $7.00 to $9.00 and gave the stock a "buy" rating in a research note on Thursday.May 30, 2025 | marketbeat.comTaysha: TSHA-102 Presses On With IND Part B Protocol And SAP AmendmentsMay 29, 2025 | seekingalpha.comTaysha stock surges on positive trial design and FDA alignmentMay 29, 2025 | investing.comStocks to Watch: Nvidia, HP, Taysha Gene TherapiesMay 29, 2025 | marketwatch.comTaysha Shares Jump 19% Following Favorable Trial Design and FDA Feedback for Rett Syndrome TherapyMay 29, 2025 | msn.comTaysha Gene Therapies, Inc. (TSHA)’s TSHA-102 Shows Promising Results in Rett Syndrome Patients Aged 6+May 29, 2025 | insidermonkey.comTaysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded WarrantsMay 28, 2025 | globenewswire.comTaysha Gene Therapies Announces Proposed Public Offering of Common Stock and Pre-Funded WarrantsMay 28, 2025 | globenewswire.comTaysha Gene Therapies Announces Pivotal Part B Trial Design Details for TSHA-102 in Rett Syndrome Enabled by IRSF Natural History Data and Positive Clinical Data from Part A of the REVEAL Adult/Adolescent and Pediatric Trials Evaluating TSHA-102May 28, 2025 | globenewswire.comTaysha Gene Therapies’ SWOT analysis: promising gene therapy stock faces pivotal yearMay 27, 2025 | investing.comTaysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives Consensus Recommendation of "Buy" from BrokeragesShares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Get Free Report) have earned an average recommendation of "Buy" from the seven research firms that are currently covering the company, MarketBeat Ratings reports. Seven analysts have rated the stock with a buy recommendation. The average 12 montMay 26, 2025 | marketbeat.comRafferty Asset Management LLC Takes $436,000 Position in Taysha Gene Therapies, Inc. (NASDAQ:TSHA)Rafferty Asset Management LLC bought a new stake in Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 252,257 shares of the company's stock, valued atMay 25, 2025 | marketbeat.comFY2025 EPS Estimates for TSHA Increased by Cantor FitzgeraldTaysha Gene Therapies, Inc. (NASDAQ:TSHA - Free Report) - Cantor Fitzgerald lifted their FY2025 EPS estimates for Taysha Gene Therapies in a note issued to investors on Monday, May 19th. Cantor Fitzgerald analyst K. Kluska now anticipates that the company will post earnings per share of ($0.36) fMay 23, 2025 | marketbeat.comVR Adviser LLC Sells 5,774,820 Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA)VR Adviser LLC reduced its position in Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Free Report) by 64.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,225,180 shares of the company's stock afterMay 22, 2025 | marketbeat.comRTW Investments LP Has $15 Million Stock Holdings in Taysha Gene Therapies, Inc. (NASDAQ:TSHA)RTW Investments LP cut its stake in Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Free Report) by 42.0% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 8,672,630 shares of the company's stock after sellingMay 18, 2025 | marketbeat.comTaysha Gene Therapies, Inc. (NASDAQ:TSHA) Q1 2025 Earnings Call TranscriptMay 16, 2025 | msn.comQ1 2025 Taysha Gene Therapies Inc Earnings CallMay 16, 2025 | finance.yahoo.comTaysha Gene Therapies Inc (TSHA) Q1 2025 Earnings Call Highlights: Promising Clinical Progress ...May 16, 2025 | finance.yahoo.comTaysha Gene Therapies Advances in Rett Syndrome TrialsMay 16, 2025 | tipranks.comTaysha outlines expedited pivotal trial start for TSHA-102 following FDA alignmentMay 15, 2025 | msn.comTaysha Gene Therapies, Inc. (TSHA) Q1 2025 Earnings Call TranscriptMay 15, 2025 | seekingalpha.com Get Taysha Gene Therapies News Delivered to You Automatically Sign up to receive the latest news and ratings for TSHA and its competitors with MarketBeat's FREE daily newsletter. Email Address TSHA Media Mentions By Week TSHA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. TSHA News Sentiment▼1.130.68▲Average Medical News Sentiment TSHA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. TSHA Articles This Week▼63▲TSHA Articles Average Week Get Taysha Gene Therapies News Delivered to You Automatically Sign up to receive the latest news and ratings for TSHA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies BHC News ARWR News DNLI News TWST News VCEL News KNSA News AGIO News SRPT News RXRX News APGE News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:TSHA) was last updated on 6/20/2025 by MarketBeat.com Staff From Our PartnersThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhen This Happens, You Don’t Wait. You Act.This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThe Biggest Story of My Decade-Long Career in Silicon ValleySteve Jobs' Lost 'Product' Could Save Tesla On July 21st, a revolutionary announcement could transform Tesl...InvestorPlace | Sponsored379 passengers walked away from thisElon Musk just wrote a $51 million check to back this material’s next phase… Because it’s not just saving l...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Taysha Gene Therapies, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Taysha Gene Therapies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
